A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
BACKGROUND:Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) provides a small but significant survival benefit. Nevertheless, controversies on applying NAC remain because the limited benefit must be weight against chemotherapy-related toxicity and the delay of definitive local...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5358850?pdf=render |
| _version_ | 1828493131547410432 |
|---|---|
| author | Kim E M van Kessel Harmen J G van de Werken Irene Lurkin Angelique C J Ziel-van der Made Ellen C Zwarthoff Joost L Boormans |
| author_facet | Kim E M van Kessel Harmen J G van de Werken Irene Lurkin Angelique C J Ziel-van der Made Ellen C Zwarthoff Joost L Boormans |
| author_sort | Kim E M van Kessel |
| collection | DOAJ |
| description | BACKGROUND:Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) provides a small but significant survival benefit. Nevertheless, controversies on applying NAC remain because the limited benefit must be weight against chemotherapy-related toxicity and the delay of definitive local treatment. Therefore, there is a clear clinical need for tools to guide treatment decisions on NAC in MIBC. Here, we aimed to validate a previously reported 20-gene expression signature that predicted lymph node-positive disease at radical cystectomy in clinically node-negative MIBC patients, which would be a justification for upfront chemotherapy. METHODS:We studied diagnostic transurethral resection of bladder tumors (dTURBT) of 150 MIBC patients (urothelial carcinoma) who were subsequently treated by radical cystectomy and pelvic lymph node dissection. RNA was isolated and the expression level of the 20 genes was determined on a qRT-PCR platform. Normalized Ct values were used to calculate a risk score to predict the presence of node-positive disease. The Cancer Genome Atlas (TCGA) RNA expression data was analyzed to subsequently validate the results. RESULTS:In a univariate regression analysis, none of the 20 genes significantly correlated with node-positive disease. The area under the curve of the risk score calculated by the 20-gene expression signature was 0.54 (95% Confidence Interval: 0.44-0.65) versus 0.67 for the model published by Smith et al. Node-negative patients had a significantly lower tumor grade at TURBT (p = 0.03), a lower pT stage (p<0.01) and less frequent lymphovascular invasion (13% versus 38%, p<0.01) at radical cystectomy than node-positive patients. In addition, in the TCGA data, none of the 20 genes was differentially expressed in node-negative versus node-positive patients. CONCLUSIONS:We conclude that a 20-gene expression signature developed for nodal staging of MIBC at radical cystectomy could not be validated on a qRT-PCR platform in a large cohort of dTURBT specimens. |
| first_indexed | 2024-12-11T11:33:35Z |
| format | Article |
| id | doaj.art-f421c434fd9243759403dc14b43319f6 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T11:33:35Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f421c434fd9243759403dc14b43319f62022-12-22T01:08:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01123e017403910.1371/journal.pone.0174039A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.Kim E M van KesselHarmen J G van de WerkenIrene LurkinAngelique C J Ziel-van der MadeEllen C ZwarthoffJoost L BoormansBACKGROUND:Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) provides a small but significant survival benefit. Nevertheless, controversies on applying NAC remain because the limited benefit must be weight against chemotherapy-related toxicity and the delay of definitive local treatment. Therefore, there is a clear clinical need for tools to guide treatment decisions on NAC in MIBC. Here, we aimed to validate a previously reported 20-gene expression signature that predicted lymph node-positive disease at radical cystectomy in clinically node-negative MIBC patients, which would be a justification for upfront chemotherapy. METHODS:We studied diagnostic transurethral resection of bladder tumors (dTURBT) of 150 MIBC patients (urothelial carcinoma) who were subsequently treated by radical cystectomy and pelvic lymph node dissection. RNA was isolated and the expression level of the 20 genes was determined on a qRT-PCR platform. Normalized Ct values were used to calculate a risk score to predict the presence of node-positive disease. The Cancer Genome Atlas (TCGA) RNA expression data was analyzed to subsequently validate the results. RESULTS:In a univariate regression analysis, none of the 20 genes significantly correlated with node-positive disease. The area under the curve of the risk score calculated by the 20-gene expression signature was 0.54 (95% Confidence Interval: 0.44-0.65) versus 0.67 for the model published by Smith et al. Node-negative patients had a significantly lower tumor grade at TURBT (p = 0.03), a lower pT stage (p<0.01) and less frequent lymphovascular invasion (13% versus 38%, p<0.01) at radical cystectomy than node-positive patients. In addition, in the TCGA data, none of the 20 genes was differentially expressed in node-negative versus node-positive patients. CONCLUSIONS:We conclude that a 20-gene expression signature developed for nodal staging of MIBC at radical cystectomy could not be validated on a qRT-PCR platform in a large cohort of dTURBT specimens.http://europepmc.org/articles/PMC5358850?pdf=render |
| spellingShingle | Kim E M van Kessel Harmen J G van de Werken Irene Lurkin Angelique C J Ziel-van der Made Ellen C Zwarthoff Joost L Boormans A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. PLoS ONE |
| title | A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. |
| title_full | A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. |
| title_fullStr | A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. |
| title_full_unstemmed | A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. |
| title_short | A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. |
| title_sort | reported 20 gene expression signature to predict lymph node positive disease at radical cystectomy for muscle invasive bladder cancer is clinically not applicable |
| url | http://europepmc.org/articles/PMC5358850?pdf=render |
| work_keys_str_mv | AT kimemvankessel areported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT harmenjgvandewerken areported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT irenelurkin areported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT angeliquecjzielvandermade areported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT ellenczwarthoff areported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT joostlboormans areported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT kimemvankessel reported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT harmenjgvandewerken reported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT irenelurkin reported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT angeliquecjzielvandermade reported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT ellenczwarthoff reported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable AT joostlboormans reported20geneexpressionsignaturetopredictlymphnodepositivediseaseatradicalcystectomyformuscleinvasivebladdercancerisclinicallynotapplicable |